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and anti-IFX antibody (ATI) concentration. We exam-
ined the correlation between loss of response, the de-
velopment of side effects or hypersensitivity, and serum 
TNF-a, IFX trough levels, and ATI concentrations. 
RESULTS: The serum TNF-a level was shown to be 
correlated with the presence of ATI; ATI positivity was 
significantly correlated with low trough levels of IFX. 
ATIs were detected in 25% of IBD patients with loss of 
response, side effects, or hypersensitivity, however no 
association was revealed between these patients and 
antibody positivity or lower serum IFX levels. Previous 
use of IFX correlated with the development of ATI, al-
though concomitant immunosuppression did not have 
any impact on them. 
CONCLUSION: On the basis of the present study, we 
suggest that the simultaneous measurement of serum 
TNF-a level, serum anti TNF-a concentration, and anti-
bodies against anti TNF-a may further help to optimize 
the therapy in critical situations.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The clinical utility of measuring serum tumor 
necrosis factor-a (TNF-a), infliximab, and anti-infliximab 
levels in the therapeutic decisions of patients with inflam-
matory bowel disease is still an outstanding question. In 
this study we assessed TNF-a, infliximab concentrations, 
and antibodies against infliximab molecules in patients 
with inflammatory bowel disease who developed loss 
of response, side effects, or allergic reaction during anti 
TNF-a therapy. Our results showed that the simultaneous 
measurement of serum TNF-a level, serum anti TNF-a 
concentration, and antibodies against anti TNF-a may 
further help to optimize therapy in critical situations.
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Abstract
AIM: To assess tumor necrosis factor-a (TNF-a), inflix-
imab (IFX) concentrations, and antibodies against IFX 
molecules in patients with inflammatory bowel disease 
(IBD) who develop loss of response, side effects, or al-
lergic reaction during anti TNF-a therapy. 
METHODS: Blood samples of 36 patients with re-
sponse loss, side effects, or hypersensitivity to IFX 
therapy (Group Ⅰ) and 31 patients in complete clinical 
remission (Group Ⅱ) selected as a control group were 
collected to measure trough serum TNF-a level, IFX, 
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two types of  inflammatory bowel disease (IBD) charac-
terized by alternating periods of  relapse and remission. 
The introduction of  anti-tumor necrosis factor (TNF)-a 
therapy caused a dramatic change in the management 
of  IBD. Approximately 40% of  patients that initially 
responded to anti-TNF-a therapy will subsequently 
lose that response, thus requiring dose intensification or 
drug change[1]. The presence of  antibodies against anti-
TNF-a agents and low drug serum concentrations have 
been implicated as predisposing factors for therapeutic 
failure. Dose intensification as a possible method for 
managing therapeutic failure is only viable in cases of  
low anti-TNF-a drug trough levels, while switching to 
another drug may be useful if  antibodies develop against 
the biological agents[2]. Immunogenicity (the formation 
of  antibodies to the biological agents) is the major cause 
of  loss of  response and adverse reactions. Scheduled 
maintenance therapy, concomitant immunomodulators 
therapy, and pretreatment with high-dose corticosteroids 
may help to reduce immunogenicity[3]. 
Although anti-drug antibodies were initially consid-
ered to play a role  in shorter response duration, recent 
studies revealed that detectable infliximab (IFX) trough 
levels, irrespective of  anti-drug antibody status, may pre-
dict to clinical response and endoscopic improvement[4,5]. 
The role of  TNF-a measurement, together with antibody 
and drug serum concentration in therapeutic decisions, 
has not previously been investigated in everyday prac-
tice; furthermore, pharmacokinetic monitoring of  IFX 
to control disease activity and optimize the treatment of  
IBD is not standardized in the daily routine. The aim of  
this study was to assess TNF-a, IFX concentrations, and 
antibodies against IFX molecules in patients with IBD 
who developed loss of  response, side effects, or allergic 
reaction during anti TNF-a therapy. 
MATERIALS AND METHODS
Study population
Sixty-seven patients with CD and UC treated in our cen-
ter with IFX between 2011 and 2012 were enrolled in 
this prospective observational study and categorized into 
two groups. Blood samples of  36 patients with response 
loss, side effects, or hypersensitivity to IFX therapy 
(Group I) and 31 patients in complete clinical remission 
(Group Ⅱ) selected as a control group were collected to 
measure trough serum TNF-a level, IFX, and anti-IFX 
antibody (ATI) concentration. The study was approved 
by the Regional and Institutional Human Medical Bio-
logical Research Ethics Committee of  the University of  
Szeged. The 3 infusion induction phase was followed by 
maintenance therapy in every patient. Data on patient 
demographics, clinical characteristics, concomitant cor-
ticosteroid and azathioprine therapies, need of  surgery, 
C-reactive protein level, erythrocyte sedimentation rate 
(ESR), hematocrit, leukocyte and serum iron levels, and 
details on biological therapy were prospectively regis-
tered. Disease activity was measured by using the Crohn’s 
disease activity index (CDAI) and partial Mayo score. The 
patients’ demographic and clinical data are summarized 
in Table 1.
We examined the correlation between loss of  response, 
side effects, or hypersensitivity and serum TNF-a, IFX 
trough levels, and ATI concentrations. 
Measurement of serum TNF-a , IFX trough levels, and 
ATI
Enzyme-linked immunosorbent assay (ELISA) was ap-
plied to determine the serum levels of  TNF-a, infliximab 
trough levels, and ATI. Blood samples were obtained pri-
or to application of  IFX infusion. Q-INFLIXI ELISA, 
Q-ATI ELISA, and Q-TNF-a ELISA kits were obtained 
from Matriks Biotek, Ankara, Turkey.
Statistical analysis
Continuous data were analyzed using medians with an 
interquartile range (IQR). All categorical data were com-
pared between groups of  patients using the Pearson χ 2 
statistic. Mann-Whitney U and Fisher’s exact tests were 
used for comparison of  infliximab trough levels and 
ATIs in a subgroup of  patients. Relation between labora-
tory parameters, IFX trough levels, and ATI was analyzed 
by Mann-Whitney U test. A P value less than 0.05 was 
considered to be significant.
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  Therapy IBD patients with 
loss of response, 
side effects, 
hypersensitivity 
(n  = 6)
Control IBD 
patients 
(n  = 1)
  Mean age at diagnosis, yr 34.9 (17-67) 36.4 (17-66)
  Mean disease duration at biological 
  therapy, yr
7.1 (1-20) 7.7 (1-21)
  CD/UC 19/17 17/14
  Male/female 14/22 14/17
  Previous biological therapy 22 15
  Concomitant steroid therapy   5   3
  Concomitant thiopurine therapy 18 16
  Previous surgery 16   7
  Active disease 25   0
Table 1  Demographic and clinical data of patients participating 
in the study
CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel 
disease.
RESULTS
The median CDAI in groups Ⅰ and Ⅱ were 138 (IQR 
68-186) and 50 (IQR 34-70), respectively; the partial 
Mayo score in the two groups were 5 (IQR 3-6) and 1 
(IQR 0-1), respectively. The median serum TNF-a levels 
were 10.5 (IQR 3.2-18-9) and 6.3 (IQR 1.5-15.7) pg/mL 
in groups Ⅰ and Ⅱ, respectively. The median IFX trough 
level was 3.1 (IQR 2.6-5.04) and 3.5 (IQR 2.6-4.7) µg/
mL in the two groups, respectively. Fourteen patients 
were found to have ATI positivity with a median of  933 
µg/mL (IQR 328-3306). ROC analysis revealed that the 
cut off  value of  serum IFX for detecting ATI was 3.01 
µg/mL. The serum TNF-a level was significantly higher 
in the presence of  ATI (24.23 pg/mL vs 6.28 pg/mL, P 
= 0.005). ATI positivity correlated significantly with low 
trough levels of  IFX (2.66 µg/mL vs 3.86 µg/mL, P = 
0.015). However, no difference was detected in serum 
IFX and antibody levels between the two groups (2.67 
µg/mL vs 2.66 µg/mL, P = 0.821). Serum IFX and ATI 
levels in patients with ATI positivity are summarized in 
Table 2. Two of  the IBD patients with antibodies against 
anti TNF-a developed side effects, 5 patients lost re-
sponse, and an allergic reaction occurred in 3 patients. 37 
patients were previously treated with biologicals, with de-
velopment of  ATI being more frequent those patients (P 
= 0.048). Dose intensification was required in 9 patients. 
No association was found between dose intensification 
and the development of  ATI. Concomitant immuno-
suppression had no impact on IFX trough levels or on 
the development of  ATI formation. Increased ESR and 
C-reactive protein correlated significantly with lower 
serum IFX level (P = 0.04 and P = 0.002). The serum 
TNF-a level was higher in patients not treated concomi-
tantly with steroids (P = 0.038).
DISCUSSION
In this prospective observational study, serum TNF-a 
level was shown to be correlated with the presence of  
ATI, and ATI positivity correlated significantly with low 
trough levels of  IFX. ATIs were detected in 25% of  IBD 
patients with loss of  response, side effects, or hypersensi-
tivity, however no association was revealed between these 
patients and antibody positivity or lower serum IFX lev-
els. Previous use of  IFX correlated with the development 
of  ATI, although concomitant immunosuppression did 
not have any impact on them. 
The prevention and management of  therapeutic fail-
ure with IFX is a significant challenge for clinicians in 
the field of  IBD. One of  the major reasons for loss of  
response is the development of  ATI, which is frequently 
caused by immunogenicity[6]. Immunogenicity induced by 
IFX can be determined by measuring antibodies, concen-
trations of  TNF-a, and IFX levels[7]. Use of  concomitant 
immunomodulators and maintenance vs episodic IFX 
therapy has previously been shown to decrease the inci-
dence of  ATI[8,9]. Baert et al[4] revealed that ATIs reduce 
serum IFX level, as well as increase the risk of  infusion 
reactions and loss of  response. The role of  ATI in loss 
of  response to IFX and the lower efficacy of  IFX re-
treatment have also been confirmed by a study by Farrell 
et al[5]. In this study, both increased TNF-a and decreased 
IFX levels correlated with the presence of  ATI, although 
neither ATI nor serum IFX influenced the outcome of  
the therapy. A recent meta-analysis also concluded that 
the presence of  ATIs is associated with a significantly 
higher risk of  loss of  clinical response to IFX and lower 
serum IFX levels in patients with IBD[10]. Although these 
statements and consequences are logical, the results of  
clinical practice are conflicting.
In a recently published systematic review, Chaparro 
et al[2] assessed the relationship between the efficacy of  
TNF-a blockers and their serum levels and the clinical 
utility of  testing for antibodies against TNF-a. A close 
relationship was revealed between trough levels of  anti-
TNF-a and maintenance of  response. Maser et al[11] did 
not  find any difference  in  the duration of  clinical  re-
sponse in patients with detectable IFX serum levels with 
or without ATI. A higher serum IFX level was proved to 
predict a longer duration of  response and clinical remis-
sion by some studies both in CD and UC[9-12]. In contrast, 
a Japanese study shown that the median trough levels 
of  IFX did not differ significantly in patients who main-
tained and lost response, suggesting a faster clearance in 
cases of  loss of  response[13]. Because of  these controver-
sial data, the usefulness of  monitoring the trough levels 
and ATI concentrations in therapeutic decisions may 
be questionable. Our results do not confirm the clinical 
utility of  trough level and antibody measurement in the 
differentiation of  “problematic” patients with loss of  
response or adverse reactions vs those who respond ap-
propriately to the biological therapy.
In a recently published study by Bortlik et al[14],  the 
median trough levels of  IFX were significantly higher 
and antibody titers significantly lower in patients with 
concomitant thiopurines. In our study, previous bio-
logical therapy had a more significant effect on the 
outcome of  IFX therapy than the concomitant use of  
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  Patients Serum IFX level (µg/mL) ATI level (µg/mL)
  1   2.75 3194.90
  2   2.68   258.55
  3   2.67 1056.25
  4   2.66 3055.04
  5   2.93 3712.82
  6   2.26 3343.07
  7   2.66   129.54
  8   2.49 4540.33
  9 12.40     58.92
  10   2.66 3679.21
  11   2.65   536.57
  12   1.90   555.53
  13   1.71   810.87
  14   4.67     46.34
Table 2  Serum infliximab and antibody levels in cases of 
antibody positivity
IFX: Infliximab; ATI: Antibody.
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16 Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouh-
nik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, 
Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud 
G, Piver E, Colombel JF, Lemann M. Maintenance of remis-
thiopurines. According to a study by Afif  et al[15], dose 
escalation was associated with a high clinical response 
in patients with subtherapeutic IFX levels and negative 
ATI, and better clinical outcome was achieved in ATI 
positive patients switching to another anti TNF-a. On 
the basis of  previous studies, concomitant corticosteroid 
therapy is suggested to decrease the effect of  TNF-a 
blocker[16,17], which was confirmed by our results regard-
ing the higher TNF-a level in patients receiving steroids. 
In conclusion, we found significant association between 
serum TNF-a level and the presence of  ATI, as well as 
between ATI positivity and low trough levels of  IFX. 
However, antibody positivity and lower serum IFX levels 
did not correlate with loss of  response, side-effects, and 
hypersensitivity. Previous use of  IFX correlated with the 
development of  ATI. When previous studies determined 
only ATI positivity or negativity, detectable IFX serum 
concentration suggested many were false-negative results. 
This factor was decreased by the quantification of  ATI 
titers in our study. On the basis of  the present work, we 
suggest that further prospective studies are needed to 
determine whether the simultaneous measurement of  
serum TNF-a level, serum anti TNF-a concentration, 
and antibodies against anti TNF-a may help to optimize 
therapy in critical situations.
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